Background/Aims: Mutations in melanocortin-4 receptor (MC4R) are the most common genetic cause of human obesity. Mutations in MC4R promoter could also underlie obesity, but have so far not been reported. Transcription factor nescient helix-loop-helix 2 (Nhlh2) is a novel obesity candidate gene. We searched for mutations in MC4R promoter and Nhlh2 gene in 152 children with severe early-onset obesity. Lean subjects (n = 447) served as controls. Methods: MC4R promoter and Nhlh2 gene were investigated by sequencing. Gel shifts and reporter gene assays were used to investigate a deletion in MC4R promoter. Mutation carriers were carefully characterised. Weight charts from index patients and relatives were analysed. Results: We identified a deletion, –439delGC, in MC4R promoter in 2 severely obese, unrelated children and their family members, but not in controls. Index patients and mutation-carrying relatives were affected by early-onset obesity, while non-carriers had normal childhood weight development. The deletion is located at a potential Nhlh2-binding site and gel shift assays showed that Nhlh2 binds to this site. No significant differences in mutant compared to wild-type MC4R promoter activities were detected. No mutations were identified in Nhlh2 gene. Conclusion: We report an MC4R promoter mutation, –439delGC, associated with early-onset obesity and show that transcription factor Nhlh2 recognises this site in vitro. Nhlh2 mutations unlikely underlie severe human obesity.

Keywords:
Melanocortin-4 receptor promoter, Mutation, Early-onset obesity, Nescient helix-loop-helix 2
1.
Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001;104:531–543.
2.
Wardlaw SL: Clinical review 127: Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 2001;86:1442–1446.
3.
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD: Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994;8:1298–1308.
4.
Schiöth HB, Lagerstrom MC, Watanobe H, Jonsson L, Vergoni AV, Ringholm A, Skarphedinsson JO, Skuladottir GV, Klovins J, Fredriksson R: Functional role, structure, and evolution of the melanocortin-4 receptor. Ann N Y Acad Sci 2003;994:74–83.
5.
Abdel-Malek ZA: Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001;58:434–441.
6.
Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P: Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000;106:253–262.
7.
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085–1095.
8.
Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, Vaisse C: Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 2003;12:145–153.
9.
Lubrano-Berthelier C, Cavazos M, Le Stunff C, Haas K, Shapiro A, Zhang S, Bougneres P, Vaisse C: The human MC4R promoter: characterization and role in obesity. Diabetes 2003;52:2996–3000.
10.
Jing E, Nillni EA, Sanchez VC, Stuart RC, Good DJ: Deletion of the Nhlh2 transcription factor decreases the levels of the anorexigenic peptides alpha melanocyte-stimulating hormone and thyrotropin-releasing hormone and implicates prohormone convertases I and II in obesity. Endocrinology 2004;145:1503–1513.
11.
Coyle CA, Jing E, Hosmer T, Powers JB, Wade G, Good DJ: Reduced voluntary activity precedes adult-onset obesity in Nhlh2 knockout mice. Physiol Behav 2002;77:387–402.
12.
Brown L, Espinosa R, 3rd, Le Beau MM, Siciliano MJ, Baer R: HEN1 and HEN2: a subgroup of basic helix-loop-helix genes that are coexpressed in a human neuroblastoma. Proc Natl Acad Sci USA 1992;89:8492–8496.
13.
Lipkowitz S, Gobel V, Varterasian ML, Nakahara K, Tchorz K, Kirsch IR: A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system. J Biol Chem 1992;267:21065–21071.
14.
Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, Buskin JN, Hauschka SD, Lassar AB, et al: Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 1989;58:537–544.
15.
Murre C, McCaw PS, Baltimore D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989;56:777–783.
16.
Massari ME, Murre C: Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000;20:429–440.
17.
Valli-Jaakola K, Lipsanen-Nyman M, Oksanen L, Hollenberg AN, Kontula K, Bjørbæk C, Schalin-Jäntti C: Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese Finnish children and adults. J Clin Endocrinol Metab 2004;89:940–945.
18.
Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P: Cardiovascular risk factor changes in Finland, 1972–1997. Int J Epidemiol 2000;29:49–56.
19.
Quandt K, Frech K, Karas H, Wingender E, Werner T: MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878–4884.
20.
Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL, Kolchanov NA: Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998;26:362–367.
21.
Kotaja N, Karvonen U, Jänne OA, Palvimo JJ: PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 2002;22:5222–5234.
22.
Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
23.
Uittenbogaard M, Peavy DR, Chiaramello A: Expression of the bHLH gene NSCL-1 suggests a role in regulating cerebellar granule cell growth and differentiation. J Neurosci Res 1999;57:770–781.
24.
Windle JJ, Weiner RI, Mellon PL: Cell lines of the pituitary gonadotrope lineage derived by targeted oncogenesis in transgenic mice. Mol Endocrinol 1990;4:597–603.
25.
Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, Gerber G, Sina M, Gorg T, Mayer H, Siegfried W, Fichter M, Remschmidt H, Hebebrand J: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 1999;84:1483–1486.
26.
Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O’Rahilly S: Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000;106:271–279.
27.
Dubern B, Clement K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, Tounian P: Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 2001;139:204–209.
28.
Mergen M, Mergen H, Ozata M, Oner R, Oner C: A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity. J Clin Endocrinol Metab 2001;86:3448.
29.
Gu W, Tu Z, Kleyn PW, Kissebah A, Duprat L, Lee J, Chin W, Maruti S, Deng N, Fisher SL, Franco LS, Burn P, Yagaloff KA, Nathan J, Heymsfield S, Albu J, Pi-Sunyer FX, Allison DB: Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 1999;48:635–639.
30.
Kobayashi H, Ogawa Y, Shintani M, Ebihara K, Shimodahira M, Iwakura T, Hino M, Ishihara T, Ikekubo K, Kurahachi H, Nakao K: A novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity. Diabetes 2002;51:243–246.
31.
Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O’Rahilly S: Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 2003;12:561–574.
32.
Marti A, Corbalan MS, Forga L, Martinez JA, Hinney A, Hebebrand J: A novel nonsense mutation in the melanocortin-4 receptor associated with obesity in a Spanish population. Int J Obes Relat Metab Disord 2003;27:385–388.
33.
Tao YX, Segaloff DL: Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 2003;144:4544–4551.
34.
Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Gruters A: Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003;52:2984–2988.
35.
Donohoue PA, Tao YX, Collins M, Yeo GS, O’Rahilly S, Segaloff DL: Deletion of codons 88–92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female. J Clin Endocrinol Metab 2003;88:5841–5845.
36.
Santini F, Maffei M, Ceccarini G, Pelosini C, Scartabelli G, Rosellini V, Chiellini C, Marsili A, Lisi S, Tonacchera M, Agretti P, Chiovato L, Mammoli C, Vitti P, Pinchera A: Genetic screening for melanocortin-4 receptor mutations in a cohort of Italian obese patients: description and functional characterization of a novel mutation. J Clin Endocrinol Metab 2004;89:904–908.
37.
Irani BG, Xiang Z, Moore MC, Mandel RJ, Haskell-Luevano C: Voluntary exercise delays monogenetic obesity and overcomes reproductive dysfunction of the melanocortin-4 receptor knockout mouse. Biochem Biophys Res Commun 2005;326:638–644.
38.
Butler AA, Cone RD: Knockout studies defining different roles for melanocortin receptors in energy homeostasis. Ann N Y Acad Sci 2003;994:240–245.
39.
Nilaweera KN, Ellis C, Barrett P, Mercer JG, Morgan PJ: Hypothalamic bHLH transcription factors are novel candidates in the regulation of energy balance. Eur J Neurosci 2002;15:644–650.
40.
Holder JL Jr, Butte NF, Zinn AR: Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet 2000;9:101–108.
41.
Liu C, Goshu E, Wells A, Fan CM: Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J Biol Chem 2003;278:44857–44867.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.